1127 POSTER Phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81422-3 ◽

2005 ◽

Vol 3 (2) ◽

pp. 325-326 ◽

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Lung Carcinoma ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Small Cell Lung Carcinoma ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Cell Lung Carcinoma

Download Full-text

O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma

Lung Cancer ◽

10.1016/s0169-5002(05)80322-8 ◽

2005 ◽

Vol 49 ◽

pp. S62-S63 ◽

Author(s):

D. Jackman ◽

J. Lucca ◽

P. Fidias ◽

M. Rabin ◽

T. Lynch ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Lung Carcinoma ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Small Cell Lung Carcinoma ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Cell Lung Carcinoma

Download Full-text

Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon

Diagnostic Cytopathology ◽

10.1002/dc.24193 ◽

2019 ◽

Author(s):

Siba El Hussein ◽

Samer N Khader

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Lung Carcinoma ◽

Kinase Inhibitor ◽

Small Cell Lung Carcinoma ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma

Thoracic Cancer ◽

10.1111/1759-7714.13378 ◽

2020 ◽

Vol 11 (4) ◽

pp. 935-942 ◽

Author(s):

Takayuki Kishikawa ◽

Takashi Kasai ◽

Masahiko Okada ◽

Ichiro Nakachi ◽

Sayo Soda ◽

...

Keyword(s):

Lung Carcinoma ◽

Kinase Inhibitor ◽

Small Cell Lung Carcinoma ◽

Third Generation ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Cell Lung Carcinoma ◽

Retrospective Multicenter Study

Download Full-text

Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7148 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7148-7148 ◽

Author(s):

D. Jackman ◽

J. Lucca ◽

P. Fidias ◽

M. S. Rabin ◽

T. J. Lynch ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase Ii ◽

Lung Carcinoma ◽

Phase Ii Study ◽

Small Cell Lung Carcinoma ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Egfr Tyrosine Kinase

Download Full-text

Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma

Lung Cancer ◽

10.1016/j.lungcan.2021.09.001 ◽

2021 ◽

Author(s):

Boudy Anne-Sophie ◽

Grausz Noémie ◽

Selleret Lise ◽

Gligorov Joseph ◽

Thomassin-Naggara Isabelle ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Lung Carcinoma ◽

Kinase Inhibitors ◽

Small Cell Lung Carcinoma ◽

Small Cell Lung ◽

Cell Lung Carcinoma

Download Full-text

A Model-Strengthened Imaging Biomarker for Survival Prediction in EGFR-Mutated Non-small-cell Lung Carcinoma Patients Treated with Tyrosine Kinase Inhibitors

Bulletin of Mathematical Biology ◽

10.1007/s11538-021-00902-7 ◽

2021 ◽

Vol 83 (6) ◽

Author(s):

Annabelle Collin ◽

Vladimir Groza ◽

Louise Missenard ◽

François Chomy ◽

Thierry Colin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Carcinoma ◽

Kinase Inhibitors ◽

Small Cell Lung Carcinoma ◽

Imaging Biomarker ◽

Survival Prediction ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Download Full-text

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1580 ◽

2020 ◽

Vol 31 ◽

pp. S818

Author(s):

M. Majem ◽

E. Felip ◽

B. Doger ◽

M. Akay ◽

E. Carcereny ◽

...

Keyword(s):

Phase Ii ◽

Lung Carcinoma ◽

Phase Ii Study ◽

Small Cell Lung Carcinoma ◽

Small Cell Lung ◽

Cell Lung Carcinoma ◽

Initial Results

Download Full-text

Calpain4 Regulates The Response Of Non-Small Cell Lung Cancer Cell Lines To EGFR Tyrosine Kinase Inhibitor Erlotinib

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6288 ◽

2012 ◽

Author(s):

Sucheta Kulkarni ◽

Leya Saju ◽

Carol F. Farver

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lung Cancer Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAÏVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS

Respirology ◽

10.1111/resp.13207_77 ◽

2017 ◽

Vol 22 ◽

pp. 114-114 ◽

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Clinical Analysis ◽

Egfr Mutations ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text